Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis

Journal of Urology

Volumn 198, Issue 3, 2017, Pages 503-510

  Boehm, Brock E ^a   Cornell, John E ^a   Wang, Hanzhang ^a   Mukherjee, Neelam ^a   Oppenheimer, Jacob S ^a   Svatek, Robert S ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

BCG vaccine; immunotherapy; urinary bladder neoplasms

Indexed keywords

BCG VACCINE; IMMUNOLOGICAL ADJUVANT;

BIOLOGICAL THERAPY; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CLINICAL TRIAL (TOPIC); HUMAN; META ANALYSIS; NETWORK META-ANALYSIS; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SYSTEMATIC REVIEW; BLADDER TUMOR; MYCOBACTERIUM BOVIS; PATHOLOGY;

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; HUMANS; MYCOBACTERIUM BOVIS; URINARY BLADDER NEOPLASMS;

EID: 85021842284     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2017.01.086     Document Type: Review

References (26)

1. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J Clin, 66, 2016, 7.
2. Hall, M.C., Chang, S.S., Dalbagni, G., et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol, 178, 2007, 2314.
3. Gan, C., Mostafid, H., Khan, M.S., et al. BCG immunotherapy for bladder cancer—the effects of substrain differences. Nat Rev Urol, 10, 2013, 580.
4. Ritz, N., Hanekom, W.A., Robins-Browne, R., et al. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev, 32, 2008, 821.
5. Fellows, G.J., Parmar, M.K., Grigor, K.M., et al. Marker tumour response to Evans and Pasteur bacille Calmette-Guérin in multiple recurrent pTa/pT1 bladder tumours: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br J Urol, 73, 1994, 639.
6. Mukherjee, A., Persad, R., Smith, P.J., Intravesical BCG treatment for superficial bladder cancer: long-term results using two different strains of BCG. Br J Urol, 69, 1992, 147.
7. Rentsch, C.A., Birkhäuser, F.D., Biot, C., et al. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol, 66, 2014, 677.
8. Sengiku, A., Ito, M., Miyazaki, Y., et al. A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. J Urol, 190, 2013, 50.
9. Witjes, W.P., Witjes, J.A., Oosterhof, G.O., et al. Update on the Dutch Cooperative Trial: Mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Semin Urol Oncol, 14(suppl.), 1996, 10.
10. Hutton, B., Salanti, G., Caldwell, D.M., et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med, 162, 2015, 777.
11. Savitski, M.M., Mathieson, T., Becher, I., et al. H-score, a mass accuracy driven rescoring approach for improved peptide identification in modification rich samples. J Proteome Res, 9, 2010, 5511.
12. Higgins J and Green S: Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. Available at http://training.cochrane.org/handbook. Accessed December 21, 2016.
13. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials, 7, 1986, 177.
14. Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 2002, 1539.
15. Salanti, G., Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods, 3, 2012, 80.
16. Chaimani, A., Higgins, J.P., Mavridis, D., et al. Graphical tools for network meta-analysis in STATA. PLoS One, 8, 2013, e76654.
17. Dias S, Welton NJ, Sutton AJ et al: NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. Available at https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0088912/pdf/PubMedHealth_PMH0088912.pdf. Accessed December 21, 2016.
18. Cookson, M.S., Herr, H.W., Zhang, Z.F., et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol, 158, 1997, 62.
19. Lu, G., Ades, A.E., Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc, 101, 2006, 447.
20. Salanti, G., Ades, A.E., Ioannidis, J.P., Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol, 64, 2011, 163.
21. Trinquart, L., Attiche, N., Bafeta, A., et al. Uncertainty in treatment rankings: reanalysis of network meta-analyses of randomized trials. Ann Intern Med, 164, 2016, 666.
22. Mostafid, A.H., Palou Redorta, J., Sylvester, R., et al. Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guérin. Eur Urol, 67, 2015, 359.
23. Lamm, D.L., Blumenstein, B.A., Crissman, J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol, 163, 2000, 1124.
24. Witjes, J.A., Dalbagni, G., Karnes, R.J., et al. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. Urol Oncol, 34, 2016, 484.e19.
25. Oddens, J., Brausi, M., Sylvester, R., et al. Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol, 63, 2013, 462.
26. Svatek, R.S., Zhao, X.R., Morales, E.E., et al. Sequential intravesical mitomycin plus bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial. Clin Cancer Res, 21, 2015, 303.